Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Chrysalis BioTherapeutics

    Client Virtual Booth

    CHRYSALIS BIOTHERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Chrysalis BioTherapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2200 Market Street, STE 609 Galveston, TX 77550
    Telephone
    Telephone
    409-497-4083
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://chrysbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/chrysalis-biotherapeutics/
    Twitter
    Twitter
    https://twitter.com/chrysbioTX

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Chrysalis Receives FDA Approval to Initiate Trials with Chrysalin™ (TP508)
    Chrysalis Receives FDA Approval to Initiate Trials with Chrysalin™ (TP508)

    https://www.businesswire.com/news/home/20230926039273/en

    BUSINESSWIRE
    26 Sep 2023
    Share Share
    Intouch Group Launches Pro-Bono Alliance with The Chrysalis Initiative
    Intouch Group Launches Pro-Bono Alliance with The Chrysalis Initiative

    https://www.prnewswire.com/news-releases/intouch-group-launches-pro-bono-alliance-with-the-chrysalis-initiative-to-shed-light-on-biased-healthcare-system-301392479.html

    PRNEWSWIRE
    05 Oct 2021
    Share Share
    Chrysalis Receives $10.4 M From BARDA to Continue Development of TP508
    Chrysalis Receives $10.4 M From BARDA to Continue Development of TP508

    https://www.businesswire.com/news/home/20201201005171/en

    BUSINESSWIRE
    01 Dec 2020
    Share Share
    Chrysalis BioTherapeutics Receives $10.4 Million From BARDA
    Chrysalis BioTherapeutics Receives $10.4 Million From BARDA

    https://www.businesswire.com/news/home/20201201005171/en/Chrysalis-BioTherapeutics-Receives-10.4-Million-From-BARDA-to-Continue-Development-of-TP508-as-a-Nuclear-Countermeasure

    BUSINESSWIRE
    01 Dec 2020
    Share Share
    Chrysalis Receives Additional Funding from the National Institutes of Health
    Chrysalis Receives Additional Funding from the National Institutes of Health

    https://www.businesswire.com/news/home/20200811005019/en/Chrysalis-BioTherapeutics-Receives-Additional-Funding-National-Institutes

    BUSINESSWIRE
    12 Aug 2020
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search